Featured Research

from universities, journals, and other organizations

Low Levels Of 'Heart Attack Risk' Protein Quantified

Date:
November 5, 2009
Source:
National Institute of Standards and Technology (NIST)
Summary:
Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person prone to a heart attack. Researchers have taken the first steps toward standardizing the measurement of a blood protein whose presence in higher-than-normal levels may predict an elevated risk for cardiovascular disease.

his is a computer-generated image of the structure for C-reactive protein.
Credit: S. Kolstoe, Center for Amyloidosis, University College, London, UK

Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person at high risk of a heart attack circulating within a haystack of human serum (liquid component of blood).

C-reactive protein (CRP), a molecule produced by the liver in response to inflammation, normally accounts for less than 1/60,000 of a person's total serum protein, or about 1 milligram per liter (mg/L) of serum. Recent evidence suggests that a CRP level between 1 and 3 mg/L indicates a moderate risk of cardiovascular disease while a level greater than 3 mg/L predicts a high risk. A clinical diagnostic procedure known as the high-sensitivity CRP (hsCRP) test has been used to detect higher-than-normal levels of the protein and warn a patient about elevated risk for cardiovascular disease. However, there is no certified reference material -- in this case, a sample of human serum with accurately determined amounts of the CRP for various risk levels -- against which the accuracy of methods for measuring CRP can be evaluated. The problem: normal, low-risk of cardiovascular disease CRP levels are so low that even mass spectrometry (a very sensitive technique for separating and identifying molecules based on mass) cannot easily quantify them.

In a recent paper in Analytical Chemistry, NIST researchers Eric Kilpatrick and David Bunk describe the first steps toward development of a certified reference material that can be used to assess the accuracy of routine clinical laboratory tests for CRP. The researchers accomplished this by isolating the minute amounts (less than 1 mg/L) of CRP circulating at normal levels in serum prior to measurement. Using a protein isolation technique called affinity purification, Kilpatrick and Bunk added polystyrene beads coated with anti-CRP antibodies to normal human serum. The antibodies bind tightly to any circulating CRP, allowing it to be easily removed from solution. The researchers then cleave the purified protein they isolated into its component parts, known as peptides, using enzyme digestion. The peptides are more readily measured by the mass spectrometer, resulting in a very precise determination of the total CRP.

To see if their purification method yields CRP that can serve as a reference material, Kilpatrick and Bunk will next mix purified CRP with genetically engineered CRP containing a heavy isotope of nitrogen (nitrogen 15) and then run the combined pool through affinity purification, enzyme digestion and mass spectrometry. The peptides with the heavy nitrogen 15 atoms will be easily detected and precisely quantified by the mass spectrometer. If the measurements for the nitrogen 15-tagged peptides compare favorably to those made for the purified serum CRP, then that will validate the use of the affinity purification method for quantifying extremely low levels of the protein. In turn, this validation will clear the way for purified serum CRP derived by the NIST method to be eventually used as a quality control and calibration tool by manufacturers for the hsCRP test.


Story Source:

The above story is based on materials provided by National Institute of Standards and Technology (NIST). Note: Materials may be edited for content and length.


Journal Reference:

  1. E.L. Kilpatrick and D.M. Bunk. Reference Measurement Procedure Development for C-Reactive Protein in Human Serum. Analytical Chemistry, 2009; 81 (20): 8610 DOI: 10.1021/ac901597h

Cite This Page:

National Institute of Standards and Technology (NIST). "Low Levels Of 'Heart Attack Risk' Protein Quantified." ScienceDaily. ScienceDaily, 5 November 2009. <www.sciencedaily.com/releases/2009/11/091104101625.htm>.
National Institute of Standards and Technology (NIST). (2009, November 5). Low Levels Of 'Heart Attack Risk' Protein Quantified. ScienceDaily. Retrieved August 29, 2014 from www.sciencedaily.com/releases/2009/11/091104101625.htm
National Institute of Standards and Technology (NIST). "Low Levels Of 'Heart Attack Risk' Protein Quantified." ScienceDaily. www.sciencedaily.com/releases/2009/11/091104101625.htm (accessed August 29, 2014).

Share This




More Health & Medicine News

Friday, August 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Killer Amoeba Found in Louisiana Water System

Killer Amoeba Found in Louisiana Water System

AP (Aug. 28, 2014) State health officials say testing has confirmed the presence of a killer amoeba in a water system serving three St. John the Baptist Parish towns. (Aug. 28) Video provided by AP
Powered by NewsLook.com
Who Could Be Burnt by WHO's E-Cigs Move?

Who Could Be Burnt by WHO's E-Cigs Move?

Reuters - Business Video Online (Aug. 28, 2014) The World Health Organisation has called for the regulation of electronic cigarettes as both tobacco and medical products. Ciara Lee looks at the impact of the move on the tobacco industry. Video provided by Reuters
Powered by NewsLook.com
CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

Newsy (Aug. 28, 2014) CDC director Tom Frieden says the Ebola outbreak is even worse than he feared. But he also said there's still hope to contain it. Video provided by Newsy
Powered by NewsLook.com
Amid Grave Ebola Estimates, US to Test Vaccine

Amid Grave Ebola Estimates, US to Test Vaccine

AP (Aug. 28, 2014) The National Institutes of Health will start the first human safety trials of an experimental Ebola vaccine next week, amid a grave estimate from the World Health Organization that Ebola cases in West Africa could top 20,000. (Aug. 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins